Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date28/02/19 → 27/02/24